Document:

EX-10.25

 Exhibit 10.25 

CYTODYN INC. 
 CONSULTING
AGREEMENT 
 This Consulting Agreement (this “Agreement”) is made and entered into effective February 21, 2014 (the
“Effective Date”), by and between CytoDyn Inc., a Colorado corporation (the “Company”), and Denis R. Burger, Ph.D., an individual (“Consultant”). 

WHEREAS, Consultant has served as an outside director of the Company’s Board of Directors (the “Board”) since February 7,
2014; 
 WHEREAS, Consultant has over 25 years of experience managing scientific, operational, financial, and executive responsibilities in
the biotech industry; and 
 WHEREAS, the Company wishes to retain Consultant to advise the Company’s executive management team (the
“Team”) and Consultant has agreed to be available for that purpose. 
 NOW, THEREFORE, in consideration of the material promises
set forth herein and for other good and valuable consideration, the parties agree as follows: 
 1. Engagement. The Company hereby
engages Consultant, and Consultant hereby accepts engagement, as an independent consultant to the Company upon the terms and conditions set forth in this Agreement. The Company and Consultant acknowledge and agree that Consultant is an independent
contractor under this Agreement and will not be an agent or employee of the Company and will have no authority to bind the Company. 
 2.
Services. During the term of this Agreement, Consultant will personally provide the following services to the Team (the “Services”). 

(a) Advising on all matters related to the Company including, but not limited to, the research, development, and clinical
studies relating to PRO 140 and other proprietary compounds; 
 (b) Attending weekly meetings with the Team at the principal
office of the Company or any other location and at a time mutually agreed to by Consultant and the Team; 
 (c) Attending
periodic meetings or telephone conference calls with the Chairman of the Board (the “Chairman”) at a time and location mutually agreed to by the Chairman and Consultant; 

(d) Upon reasonable request from the Team or Chairman, preparing reports, analyses and other written products to advise the
Team of scientific, operational, or financial matters related to the Company; and 
 (e) Reporting to the Board on the
decisions and progress of the Team. 

  
 -1- 

 3. Term. The term of this Agreement commences on the Effective Date and will end on the
earliest to occur of the following events: 
 (a) the death of Consultant; 

(b) 10 days after CytoDyn receives written notice to terminate this Agreement from Consultant or Consultant receives written
notice of termination from the Chairman; or 
 (c) Consultant ceasing to be a member of the Board. 

Notwithstanding any termination of this Agreement, the provisions of Sections 7, 8 and 9 hereof will survive indefinitely. 

4. Payments to Consultant. Consultant’s compensation hereunder will be as follows: 

(a) Monthly Fee. Consultant will receive as compensation hereunder monthly payments of $5,000, in cash, payable on or
before the 15th day of each month, beginning with the first full month during the term of this Agreement. 
 (b)
Expenses. Consultant will be entitled to be reimbursed for travel and related expenses that are pre-approved by the Chairman in writing; provided that Consultant complies with the Company’s then-current policies regarding such
reimbursement. Requests for reimbursement of any authorized expenses will be accompanied by receipts or other appropriate documentation deemed acceptable by the Company’s Chief Financial Officer to substantiate the charges in question. 

(c) Invoices; Payment. Unless otherwise agreed by the Company in writing, payment of all authorized expenses will be due
on the 15th day of the month following the month in which the invoice is received. 

(d) No Benefits. Recognizing that Consultant is an independent contractor, Consultant and the Company agree that the
Company will not be responsible for any medical, retirement or other benefits for Consultant, or for the withholding, collection, determination or payment of any tax or other imposition on the amounts due to Consultant hereunder, including, without
limitation, unemployment, payroll, social security or workers’ compensation withholdings. 
 5. Resignation from Board
Committees. Consultant hereby resigns from membership on the Board’s Compensation Committee and Nominating and Governance Committee as of the Effective Date. 

6. Confidential Information and Trade Secret Definitions. For purposes of this Agreement, “Confidential Information” is any
nonpublic knowledge or information including Trade Secret information, whether or not such is specifically identified as confidential or as a trade secret in any oral or written communication, which specifically relates to the Company’s
business and finances or the Company’s affiliates, consultants, clients, vendors, distributors, and others with whom the Company plans to do, does, or has in the past done 

  
 -2- 

 
business, which the Company deems to be confidential and proprietary, including the whole or any portion or phase of any scientific or technical information, design, process, procedure, formula,
invention (whether or not such is patentable), unpublished patent application, idea, concept, compilation, presentation, study, analysis, program, device, method, technique, improvement, or any business, regulatory, market or financial information,
or listing of names, addresses or telephone numbers, regardless of when and by whom such information was developed or acquired, and regardless of whether any of these are described in writing or fixed in tangible form, or are copyrightable,
considered copyrightable, patentable or considered patentable. Confidential Information also specifically includes information or knowledge received by the Company from others, including its consultants, vendors, clients and affiliates, which the
Company has an obligation to treat as confidential and also includes any confidential information generated or acquired by Consultant while retained by the Company. 

For purposes of this Agreement, a “Trade Secret” includes any Confidential Information that: (1) derives economic value, actual
or potential, from not being generally known to, and not being readily ascertainable by proper means by other persons who can obtain economic value from their disclosure or use; and (2) is the subject of efforts that are reasonable under the
circumstances to maintain their secrecy. 
 7. Restrictions on Use and Disclosure. Consultant will not, during the term of this
Agreement or at any time thereafter, disclose, distribute, or publish or cause to be disclosed, distributed, or published in whole or in part any Confidential Information or Trade Secrets, to any person, firm, corporation, association, or any other
operation or entity, except to employees, consultants, vendors, or agents of the Company who are authorized by the Company to receive such information and then, only on behalf of the Company and only to the extent necessary in order for Consultant
to perform faithfully his duties pursuant to this Agreement. Consultant further agrees that he will not at any time reproduce or permit the reproduction of any Confidential Information or Trade Secrets, except on behalf of the Company and then only
to the extent necessary in order for Consultant to perform his job duties and responsibilities. Consultant will take all reasonable care to avoid the unauthorized use, disclosure, publication, distribution, or reproduction of any Confidential
Information or Trade Secrets. Further, Consultant will not, during the term of this Agreement or at any time thereafter, use for his own benefit or the benefit of any other person, firm, corporation, association or other entity, or misappropriate,
or participate or assist in the misappropriation of any Confidential Information or Trade Secrets, whether for his own benefit, or the benefit of any other person, firm, corporation, association or other entity. Consultant agrees that upon the
Company’s request or instruction, Consultant will immediately either return to the Company or destroy all Confidential Information and Trade Secrets in Consultant’s possession or control, as well as all related notes, records, memoranda,
correspondence, files and other papers, and all copies or duplication (whether in writing, electronic, or digital format). 
 8. Work
Product. 
 (a) Ownership by Company. All reports, inventions, concepts, processes, methods, know-how, documentation,
improvements, technology, information, data, products and other results which Consultant may discover, conceive of, create, reduce to practice, author, develop, make, or deliver to the Company, either alone or with others, in connection with

  
 -3- 

 
Services hereunder (the “Work Product”), together with any Trade Secret or Confidential Information related thereto, shall be owned by and belong exclusively to the Company. To the
extent applicable, all Work Product shall constitute “works made for hire” by or for the Company and the Company shall be the “author” of all Work Product under applicable copyright laws. Consultant hereby assigns and conveys to
the Company any and all rights, title, interests and claims which Consultant has or may have to the Work Product and all Trade Secrets or Confidential Information related thereto. Consultant will not contest the Company’s ownership of the Work
Product, and Consultant agrees to fully cooperate and execute all instruments and documents including, but not limited to, assignments, reasonably requested by the Company to confirm, evidence or perfect its rights to the Work Product. Consultant
hereby waives any moral rights that Consultant may have in the Work Product. 
 (b) Infringement. Consultant warrants that:
(a) the Work Product will not knowingly infringe any patent, trademark, copyright, trade secret or other rights of any third party; and (b) to the best of Consultant’s knowledge, title to the Work Product will pass to the Company free
and clear of all claims, liens and interests of any third party. 
 9. Diversion of Business. Consultant will not, during the period
of this Agreement, or at any time thereafter, either for Consultant, or on behalf of any other person, firm, corporation or other operation or entity, directly or indirectly; 

(a) Business. Divert or attempt to divert from the Company or any of its affiliates any business whatsoever by
influencing or attempting to influence, or soliciting or attempting to solicit, any of the customers or strategic partners of the Company or any of the Company’s affiliates with whom Consultant may have communicated at any time; or 

(b) Employees and Affiliates. Divert or attempt to divert from the Company or any of its affiliates any person employed
by the Company or acting on behalf of or as a representative of the Company or any of its affiliates by influencing or attempting to influence such person to leave the Company’s employment or to work for or on behalf of any other business. 

10. Remedies. Consultant recognizes that a breach of any of the restrictive covenants set forth in Sections 7, 8 and 9 hereof will
cause irreparable harm to the Company and that actual damages may be difficult to ascertain and in any event may be inadequate. Accordingly, Consultant agrees that in the event of any such breach, the Company will be entitled, without the posting of
bond or other security, to injunctive relief in addition to such other legal or equitable remedies as may be available. 
 11. Compliance
with Laws. In performance of the Services, Consultant will comply with all laws, rules, regulations, applicable to Consultant and the Services, and will comply with all applicable provisions of the Company’s Code of Business Conduct and
Insider Trading Policy. 

  
 -4- 

 12. Miscellaneous. 

(a) Notices. Notices under this Agreement will be in writing and will be delivered in person, by registered or certified
mail, by overnight courier, by facsimile transmission, or by other similar means to the recipient’s address set forth below: 
  

					
	If to Consultant, to:	  	 Denis R. Burger, Ph.D.
 1534 S.W. Myrtle
Street
 Portland, Oregon 97207-1248
 Fax:
	  	
		
	If to the Company, to:	  	 CytoDyn Inc.
 Nader Pourhassan,
Ph.D.
 1111 Main Street, Suite 660
 Vancouver, Washington
98660

		
	cc.:              	  	 Miller Nash LLP 
 111
S.W. Fifth Avenue, Suite 3400
 Portland, Oregon 97204
 Attn:
Mary Ann Frantz
 Fax: (503) 224-0155

 (b) Entire Agreement. This Agreement constitutes the entire agreement of the parties
with respect to the subject matter hereof, and supersedes all previous agreements by and between the parties as well as all proposals, oral or written, and all negotiations, conversations, or discussions heretofore had between the parties related to
this agreement. 
 (c) Amendment. This Agreement will not be deemed or construed to be modified, amended, rescinded,
canceled, or waived, in whole or in part, except by written amendment signed by the parties hereto. 
 (d)
Severability. In the event that any of the terms of this Agreement are in conflict with any rule of law or statutory provision or are otherwise unenforceable under the laws or regulations of any government or subdivision thereof, such terms
will be deemed stricken from this Agreement, but such invalidity or unenforceability will not invalidate any of the other terms of this Agreement and this Agreement will continue in force, unless the invalidity or unenforceability of any such
provisions hereof does substantial harm to, or where the invalid or unenforceable provisions comprise an integral part of, or are otherwise inseparable from, the remainder of this Agreement. 

(e) Assignment. Consultant may not assign his rights or delegate his duties under this Agreement without the prior
written consent of the Company. This Agreement will be binding upon Consultant’s permitted assigns, heirs, and legal representatives, and will inure to the benefit of the Company and its successors and assigns. 

  
 -5- 

 (f) Counterparts. This Agreement may be executed in two or more
counterparts and each such counterpart will be deemed an original hereof. 
 (g) Headings. Headings and subheadings in
this Agreement are not intended to and do not have any substantive content whatsoever. 
 (h) Governing Law. This
Agreement will be governed in all respects by the laws of the state of Washington. 
 [signature page follows] 

  
 -6- 

 IN WITNESS WHEREOF, the parties have set their hands as of the Effective Date. 

 

							
	 THE COMPANY
 CytoDyn
Inc.
	 		 	 CONSULTANT
  

				
	By:	 	/s/ Anthony Caracciolo	 		 	/s/ Denis R. Burger
		 	      Anthony Caracciolo

     Chairman of the Board
	 		 	 Denis R. Burger, Ph.D.
  

  
 -7-Ex.10.1 SecAmendtoLoanAgmt

SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT 

SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT, dated as of July 9, 2014 (this “Amendment”), to the Loan and Security Agreement, dated as of February 28, 2013, as amended by the First Amendment to Loan and Security Agreement dated as of March 28, 2013 (as amended, the “Loan Agreement”), between ACF FinCo I LP, as assignee of Keltic Financial Partners II, LP, a Delaware limited partnership (the “Lender”), and Hooper Holmes, Inc., a New York corporation (the “Borrower”).  Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to such terms in the Loan Agreement. 

W I T N E S S E T H:

WHEREAS, the Borrower and the Lender are parties to the Loan Agreement, under which the Lender has agreed to make, and has made, Loans and other financial accommodations to the Borrower on the terms and subject to the conditions set forth therein; and

WHEREAS, the Borrower has requested that the Lender agree, and the Lender has agreed, to amend certain provisions of the Loan Agreement on the terms and conditions set forth herein.
NOW, THEREFORE, the Lender and the Borrower agree as follows:

SECTION 1.Amendments to the Loan Agreement.  Effective as of the date hereof, subject to the terms and conditions hereof, including, without limitation, the satisfaction of the conditions of effectiveness specified in Section 2 hereof, the Loan Agreement is amended as follows: 

(a)    Section 6.2(a) of the Loan Agreement is amended by inserting (i) “and Unbilled Eligible Receivables” after “Eligible Receivables” and (ii) “(if any)” after “open invoice”.

(b)    Section 6.3 of the Loan Agreement is amended by (i) inserting “or Unbilled Eligible Receivables” after “Eligible Receivables”.

(c)    Section 8.20 of the Loan Agreement is amended and restated in its entirety as follows: 

“8.20.  EBITDA.  Permit EBITDA as of and for each twelve (12) consecutive calendar month period ending on the last day of each Fiscal Quarter commencing with the fiscal quarter ending March 31, 2015, to be less than One Hundred Thousand and 00/100 Dollars -- $100,000.00.”

(d)    The Definitions Schedule is amended as follows:

(i)    The definition of “Borrowing Base” is amended and restated in its entirety as follows:

“Borrowing Base” means, at any time, an amount equal to:

 

(a)    an amount not to exceed eighty-five percent (85%) of the aggregate amount of Eligible Receivables (other than Unbilled Eligible Receivables) at such time;
(b)    plus, an amount not to exceed the least of (i) fifty percent  (50%) of the aggregate amount of Unbilled Eligible Receivables at such time, (ii) $2,500,000.00, and (iii) fifty percent (50%) of the Borrowing Base as most recently previously calculated under clauses (a), (b) (i) and (ii) hereof and (c) of this definition;
(c)    less, the aggregate amount of all Reserves in effect at such time.

(ii)    The definition of “EBITDA” is amended and restated in its entirety as follows:
“EBITDA” means, for any period, Borrower’s net income before interest expense, taxes, depreciation and amortization for such period, all calculated in accordance with GAAP, consistently applied and determined as of and at the end of such period.  For purposes of this Agreement, EBITDA for any period shall be determined disregarding any extraordinary items of income and expense during such period.  For purposes of this Agreement, any gains or losses resulting from the sale of any owned real estate or from all or substantially all of the assets constituting the Borrower’s “Hooper Homes Services” or “Heritage Labs” business shall not be considered extraordinary items of income or expense. 
(iii)    The definition of “Eligible Receivable” is amended as follows: (A) by inserting “other than Unbilled Receivables” between “Receivable” and “:” in the first sentence therein and (B) by amending and restating subsection (j) as follows:

“(j)  (A) any portion of the Eligible Receivables of the Account Debtor (other than an Identified Account Debtor) and its Affiliates exceeds twenty percent (20%) of the total amount of all Eligible Receivables, or (B) any portion of the Eligible Receivables of an Identified Account Debtor and its Affiliates exceeds fifty percent (50%) of the total amount of all Eligible Receivables, then the amount of such excess shall be treated as ineligible; or”

(iv)    By inserting the following new definitions in their proper alphabetical order:

“Identified Account Debtor” means an Account Debtor whose Eligible Receivables (and whose Affiliates’ Eligible Receivables) Lender in its sole discretion determines shall be treated as such under clause (j)(B) of the definition of Eligible Receivables. 
“Unbilled Eligible Receivable” means an Unbilled Receivable with respect to which Borrower’s right to payment has arisen within the last thirty (30) days and which did not arise as a result of the withdrawal, revocation, cancellation or rejection of, or any other event relating to, a previously issued invoice.
“Unbilled Receivable” means a Receivable with respect to which no invoice has been issued by Borrower.

2

(e)    Section 6 of Exhibit B to the Loan Agreement is amended and restated as set forth in Schedule 1 hereto.

SECTION 2.    Conditions of Effectiveness.  This Amendment shall become effective when, and only when, the Lender shall have received (i) a counterpart of this Amendment, Authenticated by the Borrower, (ii) an acknowledgment and consent, in the form of Exhibit A hereto, Authenticated by each of the Guarantors, (iii) payment of an amendment fee in the amount of $25,000, which shall be deemed fully earned when paid and shall be non-refundable under any circumstance, it being understood that such amendment fee was paid on or about March 27, 2014, (iv) a copy of the resolutions of the Board of Directors (or similar evidence of authorization) of the Borrower authorizing the execution, delivery and performance of this Amendment and the other agreements, instruments and documents delivered in connection herewith to which the Borrower is a party, attached to which is a certificate of the Secretary or an Assistant Secretary of the Borrower certifying the incumbency, names and true signatures of the officers of the Borrower authorized to sign this Amendment and the other agreements, instruments and documents delivered in connection herewith to which the Borrower is a party, and (v) payment of the costs and expenses (including, without limitation, attorneys’ fees) incurred by the Lender in connection with the preparation, execution and delivery of this Amendment and the agreements, instruments and documents delivered hereunder.
SECTION 3.    Representations and Warranties of the Borrower.  The Borrower represents and warrants as follows:

(a)    No Default or Event of Default has occurred and is continuing, and all of the representations set forth in Article 5 of the Loan Agreement and in the other Loan Documents are true and complete as of the date of this Amendment (except any such representation which is as of a specified date, which is accurate and complete as of such date).

(b)    The execution, delivery and performance by the Borrower of this Amendment and the agreements, instruments and other documents executed in connection herewith (i) are within the Borrower’s corporate power, (ii) have been duly authorized by all necessary or proper actions of or pertaining to the Borrower (including the consent of directors, officers, or shareholders, as applicable), (iii) are not in contravention of (A) any agreement or indenture to which the Borrower is a party or by which the Borrower is bound, (B) the Borrower’s Charter Documents, (C) any provision of law, or (D) any order, writ, judgment, injunction, or decree of any court of competent jurisdiction binding on the Borrower or its property and (iv) do not require the consent or approval of any Governmental Unit or any other Person that has not been obtained and furnished to the Lender.

(c)    No authorization, approval or other action by, and no notice to or filing with, any Person is required for the due execution, delivery and performance by the Borrower of this Amendment or any of the agreements, instruments and other documents executed in connection herewith.

(d)    This Amendment and the Loan Agreement as amended hereby constitute the legal, valid and binding obligations of the Borrower enforceable against the Borrower in accordance with their respective terms except as enforceability may be limited by (i) bankruptcy, insolvency or similar laws affecting creditors’ rights generally and (ii) general principles of equity.

SECTION 4.    Reference to and Effect on the Loan Agreement.  

3

(a)    On and after the date hereof, each reference in the Loan Agreement to “this Agreement,” “hereunder,” “hereof,” “herein” and words of like import, and each reference in the other Loan Documents to the Loan Agreement, shall mean and be a reference to the Loan Agreement as amended hereby.

(b)    Except as specifically waived or amended above, (i) the Loan Agreement and each other Loan Document shall remain in full force and effect and are hereby ratified and confirmed by the parties hereto and (ii) the Lender shall not be deemed to have waived any rights or remedies it may have under the Loan Agreement, any other Loan Document or applicable law.

(c)    The execution, delivery and effectiveness of this Amendment shall not, except as expressly provided herein, operate as an amendment to any right, power or remedy of the Lender under any of the Loan Documents, or constitute a waiver of or an amendment to any provision of any of the Loan Documents.

(d)    This Amendment constitutes a Loan Document.

SECTION 5.    Execution in Counterparts.  This Amendment may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute but one and the same instrument.

SECTION 6.    GOVERNING LAW.  THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND PERFORMED ENTIRELY IN SUCH STATE WITHOUT REGARD TO ITS PRINCIPLES OF CONFLICTS OF LAWS.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

[SIGNATURE PAGE IMMEDIATELY FOLLOWS]
        

4

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their respective general partner or officer thereunto duly authorized, as of the date first above written.
LENDER:

ACF FINCO I LP, as assignee of Keltic Financial Partners II, LP

By:    /s/ Oleh Szczupak        
     Name: Oleh Szczupak
     Title: Vice President

BORROWER:

HOOPER HOLMES, INC.

		
	By:
	/s/ Tom Collins         
Name: Tom Collins     
Title:  SVP & CFO

 

SCHEDULE 1

Concentration

(a)    Concentration – 50%:

Identified Account Debtors

Gross Accounts Receivable 
Ineligible Accounts Receivable
Eligible Accounts Receivable
Concentration Percentage            50%
Concentration Cap – Any Customer

(b)    Concentration – 20% - All other Debtors
Gross Accounts Receivable 
Ineligible Accounts Receivable
Eligible Accounts Receivable
Concentration Percentage            20%
Concentration Cap – Any Customer

	
				
	CUSTOMER NAME
	GROSS A/R
	ELIGIBLE A/R
	INELIGIBLE AMOUNT

	ABC Company
	 
	 
	 

	ABC Company
	 
	 
	 

	ABC Company
	 
	 
	 

	ABC Company
	 
	 
	 

	ABC Company
	 
	 
	 

	ABC Company
	 
	 
	 

	ABC Company
	 
	 
	 

	ABC Company
	 
	 
	 

SUB-TOTAL INELIGIBLE

 

EXHIBIT A

ACKNOWLEDGMENT AND CONSENT

Reference is hereby made to (i) the foregoing Second Amendment to Loan and Security Agreement dated as of July 9, 2014 (the “Second Amendment”) between the Lender and the Borrower.  Each of the undersigned Guarantors hereby (i) acknowledges receipt of a copy of the Second Amendment, (ii) consents to the terms thereof and (iii) agrees that the terms and provisions thereof shall not affect in any way the obligations and liabilities of such Guarantor under the Guaranty and any other Loan Documents to which it is a party, all of which obligations and liabilities shall remain in full force and effect and each of which is hereby reaffirmed.

GUARANTOR:

HERITAGE LABS INTERNATIONAL, LLC

By:    /s/ Tom Collins                
Tom Collins
Senior Vice President and Chief Financial Officer

HOOPER DISTRIBUTION SERVICES, LLC

By:    /s/ Tom Collins                
Tom Collins
Senior Vice President and Chief Financial Officer

HOOPER INFORMATION SERVICES, INC.

By:    /s/ Tom Collins                
Tom Collins
Senior Vice President and Chief Financial Officer

MID-AMERICA AGENCY SERVICES, INCORPORATED

By:    /s/ Tom Collins                
Tom Collins    
Senior Vice President and Chief Financial Officer

TEG ENTERPRISES, INC.

By:    /s/ Tom Collins                
Tom Collins
Senior Vice President and Chief Financial Officer

Dated as of July 9, 2014

-2-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}]]